NTRK
Foundation Medicine, Bristol Myers Squibb Expand CDx Partnership to Investigational Cancer Drug
The companies are working to establish FoundationOne CDx as a companion diagnostic for BMS's investigational tyrosine kinase inhibitor repotrectinib.
Illumina Adds CDx Indication to European TruSight Oncology Test for NTRK Gene Fusion Detection
The CDx pan-cancer indication will allow the identification of patients with NTRK gene fusions who may benefit from therapy with Bayer's Vitrakvi (larotrectinib).
Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
FDA Approves Foundation Medicine CDx, Bayer's Vitrakvi for NTRK Patients
The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors.
Bayer, NeoGenomics Launch Free NTRK Fusion Testing Program
The drugmaker will cover the cost of testing for up to 500 patients in the US with MSI-high colorectal cancer or RAI-refractory differentiated thyroid cancer.